Clinical Trials Directory

Trials / Unknown

UnknownNCT05811611

Two WeChat Mini Program-based Interventions Reducing Sexual Risk Behaviors Among Heterosexual Male Factory Workers

Efficacies of Two WeChat Mini Program-based Interventions in Reducing Sexual Risk Behaviors Among Heterosexual Male Factory Workers in China: a Randomized Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
244 (estimated)
Sponsor
Chinese University of Hong Kong · Academic / Other
Sex
Male
Age
18 Years
Healthy volunteers
Not accepted

Summary

A non-blinded parallel group randomized controlled trial is conducted. Adult male full-time employees of factories in Shenzhen who have access to smartphone and WeChat are recruited by staff of the Longhua Center for Disease Control and Prevention (CDC). After completing an online baseline questionnaire, participants will be randomized evenly to either the intervention group or the control group. Participants in the control group will have access to a WeChat Mini Program providing HIV and sexually transmitted prevention information during the project period. In addition to those received by the control group, the Mini Program will proactively ask participants in the intervention group some simple questions to assess presence of sexual risk behaviors at Month 0 and Month 1, and invite them to watch online health promotion video(s) tailored to their current sexual risk behaviors. All participants will complete two online follow-up surveys six and twelve months after completion of the interventions.

Conditions

Interventions

TypeNameDescription
BEHAVIORALWeChat Mini Program plus tailored online health promotion videosParticipants have access to a WeChat Mini Program. Participants will also watch online health promotion videos tailored to their current sexual behaviors.
BEHAVIORALWeChat Mini Program OnlyParticipants only have access to a WeChat Mini Program.

Timeline

Start date
2021-12-01
Primary completion
2023-04-30
Completion
2023-04-30
First posted
2023-04-13
Last updated
2023-04-13

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT05811611. Inclusion in this directory is not an endorsement.